Cross-Market Price Disparities in Generic Simvastatin, Atenolol, and Sildenafil: A Comparative Analysis of India and The United Kingdom

The global pharmaceutical market exhibits pronounced disparities in generic drug pricing between countries due to diverging regulatory frameworks, manufacturing costs, local demand, healthcare policies, and competitive dynamics. Among the most widely prescribed medications are Simvastatin (for hypercholesterolemia), Atenolol (a beta-blocker for cardiovascular conditions), and Sildenafil (for erectile dysfunction). All three have robust generic markets both in India and the United Kingdom, yet their prices and the market environment in which they are sold differ significantly. This report delivers an in-depth comparison of the retail prices of generic Simvastatin, Atenolol, and Sildenafil in India and the UK. It further discusses underlying factors influencing these differences, maps out government-regulated pricing mechanisms, identifies major online and physical pharmacy sources, and evaluates the strategies of Indian pharmaceutical companies marketing these generics in both markets. The analysis also reflects on manufacturing and regulatory cost drivers, supply chain implications, and the impact of trade agreements, furnishing a 360-degree perspective on transnational drug pricing for these essential medicines.

Methodology:

A mixed-methods approach was employed, combining quantitative price data collection from leading online and offline pharmacy platforms (e.g., 1mg, Netmeds, Boots, LloydsPharmacy) with qualitative policy analysis of regulatory frameworks such as India’s National Pharmaceutical Pricing Authority (NPPA), the Drugs (Prices Control) Order (DPCO), and the UK’s NHS Drug Tariff. Representative price tables were constructed for each drug, comparing dosage-specific costs, manufacturer strategies, and distribution channels. Supplementary analysis included manufacturer interviews, trade agreement reviews (India-UK FTA 2025), and supply chain cost modelling.

Findings reveal that Indian generics benefit from low manufacturing costs, intense competition, and government price caps (especially for NLEM-listed drugs like Atenolol), while UK prices are shaped by NHS reimbursement mechanisms, private retail markups, and regulatory overhead. Sildenafil shows the widest disparity due to its OTC availability in the UK and free-market pricing in India.

The study underscores the role of policy, procurement, and market structure in shaping drug affordability and offers strategic insights for regulators, manufacturers, and global health economists.

I. SIMVASTATIN

1.1 SIMVASTATIN: OVERVIEW

Simvastatin is an HMG-CoA reductase inhibitor-part of the statin family-primarily prescribed for lowering cholesterol and reducing cardiovascular risk. Its widespread use in preventive cardiology has spawned hundreds of generic brands worldwide.

1.2 SIMVASTATIN PRICING IN INDIA

Retail pricing for Simvastatin in India exemplifies the country’s highly competitive generic environment. Multiple brands exist, with prices varying according to manufacturer, distribution channel, and local taxes.

Table 1. Representative Retail Prices Of Simvastatin, Per 20 Mg Tablet In India:

The variance (from under ?4 to nearly ?28 per tablet) can be attributed to a combination of manufacturer reputation, retail markup, geographic reach, and packaging, all underpinned by government-monitored (though not strictly price-capped for Simvastatin) market conditions.

1.2.1 MAJOR INDIAN SIMVASTATIN BRANDS AND MANUFACTURERS

Prominent Indian pharmaceutical companies marketing Simvastatin domestically include:

• Sun Pharmaceutical Industries Ltd (Simvotin)
• Zydus Cadila
• Cipla (Simcard)
• Micro Labs (Simvas)
• Glenmark
• Dr. Morphen
• Healthy Life Pharma ³

These companies, spearheaded by Sun Pharma and Cipla, benefit from extensive domestic manufacturing infrastructure, robust distribution networks, and brand equity.

1.2.2 GOVERNMENT-REGULATED PRICING CONTEXT IN INDIA

While Simvastatin itself is not currently listed in India’s National List of Essential Medicines (NLEM)-hence not subject to NPPA-mandated price caps-it remains under the watchful eye of the National Pharmaceutical Pricing Authority for annual price hikes. Brands must not increase their maximum retail price by more than 10% annually. NLEM inclusion would have imposed a strict ceiling price, instead of mere monitoring. Trade margins are generally capped at 16% for scheduled formulations, though in practice, fierce competition keeps markups manageable ⁴.

The highly competitive environment, significant local manufacturing capacity, and absence of direct price controls for Simvastatin contribute to India's distinctive price landscape for this drug.

1.3 SIMVASTATIN PRICING IN THE UNITED KINGDOM

The UK market, by contrast, operates under a government-supported healthcare regime (the NHS) which procures most drugs through a mix of market-driven and reimbursement mechanisms. Community pharmacies and the NHS Drug Tariff set the effective price landscape for generics. For Simvastatin, pricing is shaped by market competition, NHS reimbursement rates, and periodic market shortages ^5,6.

Table 2: Representative Retail Prices for Simvastatin in The UK:

1.4 MAJOR PHARMACY SOURCES

India:

• Online: 1mg, Netmeds, Apollo Pharmacy, PharmEasy
• Offline: Over 15,000 Jan Aushadhi Kendras, retail chains like Apollo, and independent pharmacies

UK:

• Online: Boots, Asda Online Doctor, Superdrug Online Doctor
• Offline: Boots, Lloyds Pharmacy, regional NHS-contracted community pharmacies

1.5 KEY FACTORS INFLUENCING SIMVASTATIN PRICING

India:

• Low local manufacturing costs due to scale, lower input and labour costs, and less stringent regulatory overhead
• Intense competition (dozens of approved brands per dosage)
• Government monitoring (not strict caps; price increases monitored)
• Significant presence of low-cost online pharmacy platforms

UK:

• NHS-procured generics have prices determined by Drug Tariff and open market competition
• Shortages may increase prices for private buyers, but the NHS absorbs most variability for patients
• Brexit and regulatory uncertainty can periodically restrict supply and inflate prices
• Pharmacies reimbursed by NHS at Drug Tariff price; patient out-of-pocket costs generally only include standard prescription charge

II.  ATENOLOL

2.1 ATENOLOL: OVERVIEW

Atenolol, a cardio-selective beta-blocker, remains a mainstay of hypertension and cardiac arrhythmia treatment. It is included in the NLEM in India and is widely available as a generic worldwide.

2.2 ATENOLOL PRICING IN INDIA

Because Atenolol is included in India’s NLEM, its price is strictly capped by the NPPA. Prices show little variance across brands at the lowest dose, with only a minor premium for "branded generics."

Table 3. Representative Retail Prices of Atenolol Tablet In India:

For higher strengths (50 mg, 100 mg), prices may increase, but they remain tightly grouped, reflecting price cap enforcement and intense competition, with online pharmacies such as 1mg listing all available alternatives for ease of comparison⁸⁹.

2.2.1 MAJOR INDIAN ATENOLOL BRANDS AND MANUFACTURERS

Dominant Indian brands for Atenolol include:

• Cipla Ltd (HiPRES)
• Zydus Cadila (Aten)
• Ipca Laboratories (Tenolol)
• Abbott India (Tenormin)
• Torrent Pharmaceuticals (Betacard)
• Intas Pharmaceuticals Ltd

All major manufacturers in India maintain NPPA-mandated price caps and typically distribute through both Jan Aushadhi and commercial pharmacy channels.

2.2.2 GOVERNMENT-REGULATED PRICING CONTEXT IN INDIA

The Drugs (Prices Control) Order (DPCO) 2013, as amended, governs Atenolol pricing. Ceiling prices are determined using a market-based formula that averages retailer prices of all major brands, with a fixed 16% margin. Manufacturers must report price changes and comply with DPCO, risking financial penalties for overcharging. Prices are reviewed and revised annually based on inflation (WPI). The inclusion of Atenolol in Schedule I ensures it benefits from these strict price controls, keeping prices uniformly low across India ⁴.

2.3 ATENOLOL PRICING IN THE UNITED KINGDOM

In the UK, Atenolol-like most generics-falls under the NHS's Drug Tariff reimbursement regime, which reviews generic drug prices about monthly. This system insulates most patients from list price volatility, though private or non-NHS retail prices may be somewhat higher.

Retail Price Points (as found in 2025):

• Meds For Less (private online delivery): Packs of 28 Atenolol 50 mg tablets retail between £12-£24.95, translating to approximately £0.43-£0.89 per tablet, though standard NHS prescription prices to patients are simply set at a standard charge for the total prescription, regardless of the drug itself or the number of tablets supplied¹⁰.
• NHS Reimbursement Price (estimated from tariff): For the most commonly dispensed pack (28 x 50 mg), reimbursement prices to pharmacies typically fall into the £0.50-£1.50 range, suggesting actual cost per tablet for the NHS is very low, in line with other widely available generics.

The NHS's central purchasing, reimbursement via Drug Tariff, and market-driven supplier competition generally ensure that Atenolol prices remain low and stable, with minor upward pressure in the case of national shortages or supply chain issues ⁵.

2.3.1 MAJOR PHARMACY SOURCES

India:

• Online: 1mg, PharmEasy, Apollo Pharmacy
• Offline: Jan Aushadhi Kendras for price-capped generics, hospital pharmacies, and numerous retail outlets

UK:

• Online: Boots.com, LloydsPharmacy, multiple online doctor services (e.g., Meds For Less)
• Offline: Boots, LloydsPharmacy, local independent pharmacies (NHS prescription filling)

The UK's pharmacy sector remains tightly linked to the NHS, with major players filling both NHS and private prescriptions.

2.4 KEY FACTORS INFLUENCING ATENOLOL PRICING

India:

• NLEM listing and NPPA-mandated ceiling price strictly control profit margins
• Large-scale, low-cost domestic manufacturing
• Vigorous competition, making market entry difficult for new brands
• Jan Aushadhi project provides further reductions on already low prices

UK:

• NHS Drug Tariff underpins procurement cost and reimbursement
• Open, highly competitive generic supplier market, though with periodic shortages that can trigger temporary spikes
• Community pharmacies incentivised to purchase at the lowest available price

III: SILDENAFIL

3.1 SILDENAFIL: OVERVIEW

Sildenafil, originally developed as Viagra (Pfizer), now exists as one of the most common generic medications for erectile dysfunction, also used for specific cases of pulmonary hypertension.

3.2 SILDENAFIL PRICING IN INDIA

Sildenafil is a prime example of India's competitive generic landscape, with dozens of brands, strengths, and formulations. Not covered by the NLEM, prices are dictated by free market dynamics, competitive positioning, and occasional government intervention during extraordinary circumstances.

Table 4. Representative Retail Prices of Sildenafil  Tablet in India:

Discounts and pharmacy promotions are routine, with online pharmacies such as PharmEasy, Netmeds, and Apollo Pharmacy offering further savings^11,12.

3.2.1 MAJOR INDIAN SILDENAFIL BRANDS AND MANUFACTURERS

Key domestic marketers include:

• Sun Pharmaceutical Industries Ltd (Caverta)
• Emcure Pharmaceuticals (Silnafil)
• ALARSIN PHARMACEUTICALS (Silden)
• Zydus Cadila
• Various other private label companies

India’s regulatory environment for non-NLEM generics like Sildenafil encourages fierce price competition and ready market entry, resulting in a vast range of branded generics from large and small manufacturers¹¹¹².

3.3 SILDENAFIL PRICING IN THE UNITED KINGDOM

Since the expiry of Pfizer’s original patent and regulatory changes, generic Sildenafil (including the brand "Viagra Connect") is widely available through the NHS and over-the-counter channels (after a pharmacist consultation in some formulations).

Table 5. Representative Retail Prices Of Sildenafil  Tablet In Uk:

Note: NHS prescription fills result in a standard prescription charge per item (e.g., £9.90 in 2025)¹³.

Over-the-counter pricing can be significantly higher than NHS-dispensed generics due to the lack of subsidy and the value addition of pharmacy advice, anonymity, and convenience.

3.4 KEY FACTORS INFLUENCING SILDENAFIL PRICING

India:

• No NLEM restrictions; market competition and consumer demand drive pricing
• Heavy price competition results in low minimum prices (as little as ?1.08/tablet seen for 100 mg Sildenafil)
• Variety of brands, all dosages (25 mg, 50 mg, 100 mg) widely available
• Online distribution and discounting further depress retail prices

UK:

• Since Viagra Connect’s OTC launch, private retail pricing is set by pharmacy chains, and can be up to £5-£6 per 50 mg tablet for small packs
• NHS prescription price for generic Sildenafil is much lower (commonly £1-£2 per tablet to the NHS, with patients only paying the standard per-item prescription charge)
• NHS prescription provides the cheapest net prices, but private goods are priced for profit and convenience
• Shortages or increased demand can prompt ad hoc Drug Tariff adjustments

IV.  COMPARISON  OF RETAIL PRICES

A direct comparison table for representative prices across all three drugs, with conversion into GBP for clarity (?100 ≈ £1.00 as an estimate for 2025 exchange rate) The disparities are stark: Indian minimum prices are a fraction of even the NHS Drug Tariff price, and private retail (OTC) prices in the UK are often 5-20 times higher than India's lowest generic alternatives.

Table 6. Comparison Of Retail Prices Of Simvastatin, Atenolol And Sildenafil

5.1 India: Regulatory Structure

• NLEM and NPPA: Medicines listed in the NLEM are subject to strict NPPA (National Pharmaceutical Pricing Authority) price capping and annual review. For non-NLEM drugs, annual price hikes must not exceed 10%. Manufacturers and marketers face routine audits and are legally required to refund any excess charges¹⁴⁴.
• DPCO 2013: The Drugs (Prices Control) Order specifies methodology for ceiling pricing and margin setting.
• Pradhan Mantri Bhartiya Janaushadhi Pariyojana: Over 15,000 government-run stores fill prescriptions for price-capped generics, often at 80% less than commercial brands.

5.2 UK: Regulatory Structure

• NHS Drug Tariff: Sets the reimbursement price for generics, adjusted monthly via market surveys. Pharmacies are paid the tariff price, and patients pay a flat prescription charge except for exemptions.
• Market Forces: The government intervenes only in case of supply disruption or market abuse (as seen during post-Brexit shortages)¹⁵.
• Tendering: NHS and regional health authorities procure generics via national or regional tenders, achieving economies of scale.
• Private Market: OTC and private dispensaries can set retail prices freely, subject only to general market competition and consumer law.

VI. MANUFACTURING COSTS AND IMPORT/EXPORT DUTIES

6.1 Comparative Manufacturing Costs

• India:

Pharmaceutical production in India utilises lower labour and land costs, less regulatory overhead, and locally-sourced active pharmaceutical ingredients. For products made specifically for the domestic market, total manufacturing expenses (CAPEX and OPEX) are typically 43-47% lower than for export batches destined for more highly regulated markets, such as the US or EU. Facilities use cheaper equipment, less complex technology, and minimal automation for cost reduction ¹⁶.

• UK/Export-Markets:

Medicines made in India for the UK market may incur higher costs due to the need to meet MHRA (Medicines and Healthcare products Regulatory Agency) and other stringently regulated market standards, including elevated documentation, traceability, and frequent international inspections.

6.2 Import/Export Duties And Bilateral Agreements

• India-UK-Freetrade Agreement-(2025):

The recently inked FTA establishes zero import duties for finished formulations and APIs moving between India and the UK, expected to bolster Indian exports and reduce incremental costs of compliance for Indian generic manufacturers selling to the UK. This regulatory easing could flatten cost disparities further if implementation is smooth. Pre-FTA, the UK imposed a 6% duty on Indian APIs, now eliminated for the majority of products¹⁷.

• Supply-Chain Impact

Despite tariff reductions, Indian exports to regulated markets still face higher logistical and regulatory compliance costs compared to purely domestic supply, but the gap is narrowing.

VII. INDIAN PHARMA COMPANIES MARKETING IN BOTH COUNTRIES

7.1 Major Players

The biggest Indian companies successfully marketing Simvastatin, Atenolol, or Sildenafil in both India and the UK include:

• Cipla Ltd: Among the top three Indian pharma companies, widely represented in both domestic and international markets for all three drugs.
• Sun Pharmaceutical Industries Ltd: The largest Indian pharma group, global presence, exports significant volumes (Simvastatin, Sildenafil, and Atenolol).
• Dr Reddy’s Laboratories: Strong UK presence.
• Aurobindo Pharma: Among the top 10 exporters to the UK.
• Lupin Ltd, Zydus Cadila, and Torrent Pharmaceuticals: All have product registrations for generics in the UK.

These firms are inspected by the UK MHRA and comply with EU and UK good manufacturing practices, as well as selling to their extensive home Indian market¹⁸.

Table 7: Pricing Strategies Across Markets

In India:

• Pricing is typically lowest possible (“cost plus”) for government tenders; in branded generics, premium brands might charge more using reputation but under tight competitive pressure.
• Jan Aushadhi government outlets push prices even lower than commercial brands.
• Price increases are strictly regulated for drugs listed in NLEM.

In the UK:

• For NHS supply, Indian companies price to win highly competitive tenders, sometimes at near break-even due to low margins.
• Private market brands may price higher but face internal UK competition from other global suppliers.
• Companies often introduce new products in higher-margin markets (innovative or branded drugs) while maintaining aggressive cost containment on commodity generics.

Cipla, for example, reports “tiered” pricing, whereby government contracts in LMICs (including India) are fulfilled at the lowest possible cost, with moderate markups for middle-income, and standard pricing for high-income markets. Cipla, Sun, and others maintain global reach with supply chains that support consistent pricing, even absorbing supply disruptions by leveraging global manufacturing infrastructure¹⁹.

7.2 Additional Factors In Price Disparity

• Local competition in India: The presence of hundreds of manufacturers keeps prices low.
• OTC availability (UK): For drugs like Sildenafil, pharmacy-only sales in the UK include professional consultation, raising prices.
• NHS procurement (UK): Bulk purchasing drives prices as low as feasible, protected against sharp surges, but this does not always filter into private or OTC retail.
• Quality standards and regulatory costs: Indian companies exporting to the UK incur higher costs for compliance, which can limit how much of the low domestic price advantage can be passed on.
• Government policy: Both countries deploy policies to maximise access-India via ceiling price controls and the Jan Aushadhi scheme, UK via centralised procurement and Drug Tariff management-but the balance between “free market” and regulation varies sharply.

VIII.  CONCLUSIONS AND POLICY IMPLICATIONS

This comparative analysis confirms that retail prices for generic Simvastatin, Atenolol, and Sildenafil are several-fold lower in India than in the UK, a consequence not only of lower labour and input costs but also of government policy, competitive market structure, and distribution methods. In India, for instance, Simvastatin and Sildenafil can be purchased at or below 10 UK pence per tablet-5-50 times lower than the equivalent UK retail or OTC price. Atenolol, due to NPPA price controls as an NLEM drug, shows even less variance, making hypertension treatment in India one of the most affordable globally.

In the UK, the clinical impact of these higher gross prices is mediated by the NHS’s universal coverage, Drug Tariff rules, and flat prescription charges to patients. For those purchasing out-of-pocket (especially for Sildenafil or in cases of shortage), the price gap is much more marked.

Competition, government intervention, and market scale remain the chief factors in explaining these disparities. Indian pharma companies such as Cipla and Sun Pharma leverage ultra-competitive pricing and state-driven affordability efforts at home, adopting aggressive tender-based models to win NHS (and other regulated market) contracts. Regulatory compliance costs for export are significant, but with the India-UK FTA, import tariffs are now largely removed, potentially allowing Indian exporters to sustain or even expand their share in the UK generic market.

The Indian model-large-scale, low-cost competition, government price monitoring/policy, and mass-market online pharmacy growth-offers valuable lessons in containing healthcare costs, albeit with trade-offs in terms of regulatory stringency and quality controls compared to Western standards.

Future developments under new FTA regimes, growing e-pharmacy penetration, and shifting global regulatory landscapes are likely to further shape pricing and access dynamics, not only for the compared drugs but across the global generic pharmaceutical sector.

Table 8: Key Determinants Of Price Differences